NXP200 — IND submission
Late 2026
We look forward to further updates from the ongoing Phase 1b program, including in additional tumor types, and we remain on track to submit a U.S. IND for NXP200 by the end of this year.Source filing
NVCT biotech catalysts & pipeline
NUVECTIS PHARMA INC · Data as of 2026-10-27
Upcoming catalysts
NXP900 — Interim data
Late 2026
Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year.Source filing
ciprocopan — FDA meeting
4Q2026
U.S. regulatory efforts underway; a pre-investigation new drug ("IND") meeting with the Food and Drug Administration ("FDA") followed by IND submission expected in 4Q2026.Source filing
NXP200 — Conference presentation
Oct 23–Oct 27
Oral presentation of additional clinical data generated by Haisco will be presented at the upcoming European Society for Medical Oncology (ESMO) conference (Madrid, Spain, October 23–27, 2026).Source filing